Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells.
OBJECTIVE
The present study aimed to compare the gene-expression profiling of CD133(+) and CD133(-) D10 cells.


METHODS
Cancer stem cell-like properties and gene-expression profiling of CD133(+) D10 cells versus CD133(-) cells were evaluated.


RESULTS
The CD133(+) D10 cells showed significantly higher clonogenic and spheroid forming potential, also higher expression of stemness genes NANOG and OCT4A compared with the CD133(-) cells. Gene-expression profiling of CD133(+) versus CD133(-) D10 cells revealed that 130 genes including ABC transporter superfamily (ABCC1, ABCG2 and ABCC6) were upregulated, while 61 genes including apoptosis modifying genes (CASP8 and TNFRSF4) were downregulated.


CONCLUSIONS
We conclude that many genes involved in drug resistance and tumor aggressiveness are upregulated in CD133(+) D10 cells and targeting them might be an efficient strategy for treatment of melanoma.
Oncopathology Research Center, Iran University of Medical Sciences, Hemmat Street (Highway), Next to Milad Tower, Tehran 14496-14530, Iran.|Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Raheleh
R
Roudi
Department of Stem Cells & Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology & Technology, ACECR, Tehran, Iran.
Marzieh
M
Ebrahimi
Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mehrdad Nasrollahzadeh
MN
Sabet
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ali
A
Najafi
Genomics Division, Systems Biology Institute, Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohamad Reza
MR
Nourani
Department of Stem Cells & Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology & Technology, ACECR, Tehran, Iran.
Motahareh Rajabi
MR
Fomeshi
Cellular & Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.|Department of Tissue Engineering & Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ali
A
Samadikuchaksaraei
Department of Nuclear Medicine & Molecular Imaging, State University of New York at Buffalo, NY, USA.
Ahmad
A
Shariftabrizi
Oncopathology Research Center, Iran University of Medical Sciences, Hemmat Street (Highway), Next to Milad Tower, Tehran 14496-14530, Iran.|Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Zahra
Z
Madjd
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000235:genetics* / Q000378:metabolism*; D014408:Biomarkers, Tumor; D045744:Cell Line, Tumor; D019295:Computational Biology / Q000379:methods; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006023:Glycoproteins / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D016130:Immunophenotyping; D008545:Melanoma / Q000235:genetics* / Q000378:metabolism*; D010455:Peptides / Q000235:genetics* / Q000378:metabolism*; D025941:Protein Interaction Mapping; D060066:Protein Interaction Maps; D059467:Transcriptome
D000071916:AC133 Antigen; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides
CD133; D10 cell line; cDNA microarray; cancer stem cells; melanoma